CONTACT US
Home > Inhibitors/Agonists>Antibacterials>Bacterial> > AFN-1252
620175-39-5-AFN-1252 AFN-1252

AFN-1252

For research use only. Not for therapeutic Use.

  • CAT Number: I004343
  • CAS Number: 620175-39-5
  • Molecular Formula: C22H21N3O3
  • Molecular Weight: 375.42
  • Purity: ≥95%
Inquiry Now
Related Small Molecules: DMU2105     Buclizine HCl     N,N,N-Trimethylpropan-1-aminium bromide    

AFN-1252（Cat No.:I004343）is a novel antibiotic specifically targeting Staphylococcus aureus, including methicillin-resistant strains (MRSA). It inhibits fatty acid synthase II (FASII), an enzyme critical for bacterial membrane synthesis, without affecting human cells, making it highly selective and reducing off-target effects. In research, AFN-1252 is valuable for studying targeted antimicrobial strategies and the development of narrow-spectrum antibiotics. Its unique mechanism and specificity offer promise in addressing resistant bacterial infections, making it a key candidate for understanding and combatting staphylococcal pathogens in focused therapeutic research.


Catalog Number I004343
CAS Number 620175-39-5
Synonyms

AFN-1252; AFN1252;

Molecular Formula C22H21N3O3
Purity ≥95%
Target Bacterial; Antibiotic
Solubility DMSO: ≤ 5.8 mg/mL(Need ultrasonic)
Storage Store at -20°C
IUPAC Name (E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-6,8-dihydro-5H-1,8-naphthyridin-3-yl)prop-2-enamide
InChI InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+
InChIKey QXTWSUQCXCWEHF-JXMROGBWSA-N
SMILES CC1=C(OC2=CC=CC=C12)CN(C)C(=O)/C=C/C3=CC4=C(NC(=O)CC4)N=C3
Reference

<br />
1:Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities. Hafkin B, Kaplan N, Murphy B.Antimicrob Agents Chemother. 2015 Dec 28;60(3):1695-701. doi: 10.1128/AAC.01741-15. PMID: 26711777 Free PMC Article<br />
2:Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects. Hunt T, Kaplan N, Hafkin B.J Chemother. 2016 Jun;28(3):164-71. doi: 10.1179/1973947815Y.0000000075. Epub 2016 May 13. PMID: 26431470 <br />
3:Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects. Hafkin B, Kaplan N, Hunt TL.Future Microbiol. 2015;10(11):1805-13. doi: 10.2217/fmb.15.101. Epub 2015 Sep 11. PMID: 26357940 <br />
4:AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei–Crystal structure, mode of action, and biological activity. Rao KN, Lakshminarasimhan A, Joseph S, Lekshmi SU, Lau MS, Takhi M, Sreenivas K, Nathan S, Yusof R, Abd Rahman N, Ramachandra M, Antony T, Subramanya H.Protein Sci. 2015 May;24(5):832-40. doi: 10.1002/pro.2655. Epub 2015 Apr 2. PMID: 25644789 Free PMC Article<br />
5:Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). Yao J, Maxwell JB, Rock CO.J Biol Chem. 2013 Dec 20;288(51):36261-71. doi: 10.1074/jbc.M113.512905. Epub 2013 Nov 4. PMID: 24189061 Free PMC Article<br />
6:AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. Kaplan N, Garner C, Hafkin B.Eur J Pharm Sci. 2013 Nov 20;50(3-4):440-6. doi: 10.1016/j.ejps.2013.08.019. Epub 2013 Aug 27. Erratum in: Eur J Pharm Sci. 2014 Feb 14;52:223. PMID: 23988847 <br />
7:Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO.Antimicrob Agents Chemother. 2013 May;57(5):2182-90. doi: 10.1128/AAC.02307-12. Epub 2013 Mar 4. PMID: 23459481 Free PMC Article<br />
8:Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. Tsuji BT, Harigaya Y, Lesse AJ, Forrest A, Ngo D.J Chemother. 2013 Feb;25(1):32-5. doi: 10.1179/1973947812Y.0000000060. PMID: 23433442 Free PMC Article<br />
9:Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. Banevicius MA, Kaplan N, Hafkin B, Nicolau DP.J Chemother. 2013 Feb;25(1):26-31. doi: 10.1179/1973947812Y.0000000061. PMID: 23433441 Free PMC Article<br />
10:In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics. Kaplan N, Awrey D, Bardouniotis E, Berman J, Yethon J, Pauls HW, Hafkin B.J Chemother. 2013 Feb;25(1):18-25. doi: 10.1179/1973947812Y.0000000063. PMID: 23433440 Free PMC Article

Request a Quote